Evidence map›Paper›PMID 28679559›Full record

Trial reportJournal of the American Heart Association2017

Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.

Marco Dauriz, Giovanni Targher, Pier Luigi Temporelli, Donata Lucci, Lucio Gonzini, Gian Luigi Nicolosi, Roberto Marchioli, Gianni Tognoni, Roberto Latini, Franco Cosmi and 3 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00336336. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00336336 phase3completed

A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure

Ran2002Enrolled6,975Registered outcomes10Posted comparisons0ConditionsHeart FailureArmsn-3 PUFA, Placebo, Rosuvastatin
PMID 18757089PMID 15302013PMID 18757090other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Marco DaurizDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Giovanni TargherDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Pier Luigi TemporelliDivision of Cardiology, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno, Italy.
Donata LucciANMCO Research Center, Florence, Italy.
Lucio GonziniANMCO Research Center, Florence, Italy.
Gian Luigi NicolosiDepartment of Cardiology, Santa Maria degli Angeli Hospital, Pordenone, Italy.
Roberto MarchioliTherapeutic Science and Strategy Unit (TSSU), Quintiles, Milan, Italy.
Gianni TognoniDepartment of Cardiovascular Research, IRCCS-Istituto di Ricerche Famacologiche Mario Negri, Milan, Italy.
Roberto LatiniDepartment of Cardiovascular Research, IRCCS-Istituto di Ricerche Famacologiche Mario Negri, Milan, Italy.
Franco CosmiDivision of Cardiology, Ospedale Valdichiana Santa Margherita, Cortona, Italy.
Luigi TavazziMaria Cecilia Hospital, GVM Care & Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy.
Aldo Pietro MaggioniANMCO Research Center, Florence, Italy maggioni@anmco.it.
GISSI‐HF Investigators
Associazione Nazionale Medici Cardiologi Ospedalieri · ITMaria Cecilia Hospital · ITIstituti Clinici Scientifici Maugeri · ITMario Negri Institute for Pharmacological Research · ITAzienda Ospedaliera Santa Maria Degli Angeli · ITAzienda Ospedaliera Universitaria Integrata Verona · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIQVIA (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe independent prognostic impact of diabetes mellitus (DM) and prediabetes mellitus (pre-DM) on survival outcomes in patients with chronic heart failure has been investigated in observational registries and randomized, clinical trials, but the results have been often inconclusive or conflicting. We examined the independent prognostic impact of DM and pre-DM on survival outcomes in the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. METHODS AND

resultsWe assessed the risk of all-cause death and the composite of all-cause death or cardiovascular hospitalization over a median follow-up period of 3.9 years among the 6935 chronic heart failure participants of the GISSI-HF trial, who were stratified by presence of DM (n=2852), pre-DM (n=2013), and non-DM (n=2070) at baseline. Compared with non-DM patients, those with DM had remarkably higher incidence rates of all-cause death (34.5% versus 24.6%) and the composite end point (63.6% versus 54.7%). Conversely, both event rates were similar between non-DM patients and those with pre-DM. Cox regression analysis showed that DM, but not pre-DM, was associated with an increased risk of all-cause death (adjusted hazard ratio, 1.43; 95% CI, 1.28-1.60) and of the composite end point (adjusted hazard ratio, 1.23; 95% CI, 1.13-1.32), independently of established risk factors. In the DM subgroup, higher hemoglobin A1c was also independently associated with increased risk of both study outcomes (all-cause death: adjusted hazard ratio, 1.21; 95% CI, 1.02-1.43; and composite end point: adjusted hazard ratio, 1.14; 95% CI, 1.01-1.29, respectively).

conclusionsPresence of DM was independently associated with poor long-term survival outcomes in patients with chronic heart failure. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00336336.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersBlood GlucoseCause of DeathChronic DiseaseDiabetes MellitusDouble-Blind MethodFatty Acids, Omega-3FemaleGlycated HemoglobinHeart FailureHospitalizationHumansBiomarkersBlood GlucoseFatty Acids, Omega-3Glycated Hemoglobinhemoglobin A1c protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin Calciumchronic heart failurediabetes mellitusglycemic controlheart failuremortalityprediabetes

Identifiers

PMID28679559
PMCPMC5586270
OpenAlexW2730880147

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.